<p>Ask us your questions about our products, patient materials or organising a meeting.</p>


<strong><span class="text-body-1"><span class="text-white">Sanofi is here to support you and your patients</span></span></strong>

<h3>Toujeo® DoubleStar™<br>
  (insulin glargine 300 units/mL)</h3>
<p><u><a href="${link:{uuid:{f34a87f8-75d0-4459-a2d8-c10d6469758f},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo-combined.pdf}}}">Prescribing information</a></u></p>

<h3>Toujeo® SoloStar™<br>
  (insulin glargine 300 units/mL)</h3>
<p><u><a href="${link:{uuid:{f34a87f8-75d0-4459-a2d8-c10d6469758f},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo-combined.pdf}}}">Prescribing information</a></u></p>

<h3>Lantus® SoloStar™<br>
  (insulin glargine 100 units/mL)</h3>
<p><u><a href="${link:{uuid:{8f132346-a5c2-470d-8368-64ab56220e08},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB_NI_PI.pdf}}}">Prescribing information</a></u></p>

<h3>Admelog®<br>
  (insulin lispro 100 units/mL)</h3>
<h3><u><span class="text-primary3"><strong><span class="text-body-5 text-orange">This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.</span></strong></span></u></h3>

<h3>Trurapi®▼<br>
  (insulin aspart 100 units/mL)</h3>
<h3><u><span class="text-primary3"><strong><span class="text-body-5 text-orange">This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.</span></strong></span></u></h3>

TYPE-1-DIABETES

TYPE-2-DIABETES

DIABETES

Diabetes patient support

<p><a href="${link:{uuid:{6d9c94f2-d265-455c-8c68-c6baa36eb18a},repository:{dam},path:{/Portal/UK/Prescribing-links/Avaxim-PI-UK-January-2022.pdf}}}" target="_blank">AVAXIM<sup>®</sup> Hepatitis A vaccine (inactivated, adsorbed) Prescribing Information</a><br><a href="${link:{uuid:{82beb05d-e161-4977-badb-84e48203da79},repository:{dam},path:{/Portal/UK/Prescribing-links/Avaxim-Junior-PI-GB-NI-June-2023.pdf}}}" target="_blank">AVAXIM<sup>®</sup> Junior Hepatitis A vaccine (inactivated, adsorbed)&nbsp;Prescribing Information</a></p>

<h2>Why run a Hepatitis A vaccine booster campaign?</h2>

<p>While most travellers focus on their first Hepatitis A dose, some may not return for their second (booster) dose.</p>
<p>The booster dose provides travel clinics with an opportunity to help protect patients aged 16 years and above against Hepatitis A beyond 10 years.</p>
<p>In patients from 16 years of age, this can be achieved with AVAXIM Hepatitis A vaccine (inactivated, adsorbed). Before you prescribe this vaccine please refer to the&nbsp;<a href="${link:{uuid:{6d9c94f2-d265-455c-8c68-c6baa36eb18a},repository:{dam},path:{/Portal/UK/Prescribing-links/Avaxim-PI-UK-January-2022.pdf}}}" target="_blank">Prescribing Information</a>&nbsp;and&nbsp;<a href="https://www.medicines.org.uk/emc/product/1394/smpc">SmPC</a>.</p>
<p>In patients aged 1 -15 years this can be achieved with AVAXIM Junior Hepatitis A vaccine (inactivated, adsorbed). Before you prescribe this vaccine please refer to the&nbsp;<a href="${link:{uuid:{82beb05d-e161-4977-badb-84e48203da79},repository:{dam},path:{/Portal/UK/Prescribing-links/Avaxim-Junior-PI-GB-NI-June-2023.pdf}}}" target="_blank">Prescribing Information</a>&nbsp;and&nbsp;<a href="https://www.medicines.org.uk/emc/product/14684">SmPC</a>.</p>
<p>A booster dose of Hepatitis A vaccine can be given, ideally at 6 to 12 months, and no later than 36 months, after the initial dose in order to help provide protection beyond ten years.</p>

<h2>Suggestions on how to run a booster campaign</h2>
<h3><strong><strong><b>Team planning</b></strong></strong></h3>
<p>Hold a meeting with the relevant team members to align on the benefits of running a Hepatitis A booster campaign.</p>
<h3><strong><strong><b>Identify patients</b></strong></strong></h3>
<p>Run a report from your patient records to identify those eligible patients who haven't received a 2nd dose of a Hepatitis A vaccine in the last 36 months.</p>
<h3><strong><strong><strong><b>Make contact either by:</b></strong></strong></strong></h3>
<ul>
 <li>Utilising your recall system to initiate an Email/Phone/SMS invitation</li>
 <li>Creating a pop up alert on their patient record</li>
 <li>Contacting them via post</li>
</ul>
<h3><strong><strong><b>Logistics</b></strong></strong></h3>
<ul>
 <li>Schedule dedicated time for your travel nurse to run the Hepatitis A campaign</li>
</ul>
<h3><strong><strong><b>Patient support</b></strong></strong></h3>
<ul>
 <li>Ensure you have a sufficient supply of patient support materials including travel record cards</li>
 <li><strong><a href="https://www.medisa.com/medisa/" target="_blank">Visit Medisa</a></strong>&nbsp;to order patient materials online</li>
</ul>
<h3><strong><strong><b>Supply</b></strong></strong></h3>
<ul>
 <li>Ensure you have sufficient supply of&nbsp;<a href="/uk/products/avaxim"><strong>AVAXIM</strong></a>&nbsp;or&nbsp;<strong><a href="${link:{uuid:{d2b75c86-6b21-4467-9831-d917173012cf},repository:{products},path:{/UK/avaxim-junior}}}" target="_self">AVAXIM&nbsp;Junior</a></strong>&nbsp;- &nbsp;find out more about&nbsp;<a href="/uk/other-vaccines-topics/resources/vaccines-ways-to-order"><strong>ways to order</strong></a>&nbsp;or&nbsp;<strong><a href="https://www.vaxishop.co.uk/vaxishop/en/GBP/login?site=vaxishop">visit VaxiShop</a></strong>.</li>
</ul>
<h3><strong><strong>Assess and Administer</strong></strong></h3>
<ul>
 <li>Consider using&nbsp;<strong><a href="${link:{uuid:{53319e2d-915b-45f2-927e-6e669404aaf2},repository:{products},path:{/UK/avaxim}}}" target="_self">AVAXIM</a></strong>
  <ul>
   <li>In patients aged 16 years and above who received a monovalent Hepatitis A vaccine, or a combined Hepatitis A and Typhoid fever vaccine 36 months (preferably 6-12 months) previously.</li>
  </ul></li>
 <li>Consider using&nbsp;<strong><a href="${link:{uuid:{d2b75c86-6b21-4467-9831-d917173012cf},repository:{products},path:{/UK/avaxim-junior}}}" target="_self">AVAXIM&nbsp;Junior</a></strong>: 
  <ul>
   <li>In children aged 1-15 years for active immunisation against infection caused by the Hepatitis A virus</li>
  </ul></li>
</ul>

<p>You can order Sanofi Vaccines in two ways: online at VAXISHOP or through our call centre.&nbsp;<a href="/uk/other-vaccines-topics/resources/vaccines-ways-to-order">Read more about ordering vaccines</a>.&nbsp;</p>

<p><a href="tel:+44 (0) 800854430" target="_self">CALL 0800854430</a></p>


Ways to order

TRAVEL

VACCINES

Hepatitis A Booster Campaigns

A short animation to support your patient discussions on herd immunity for flu, and why flu vaccination is important to help protect them, their loved ones and their communities.

INFLUENZA

Herd immunity for flu

<p><a href="${link:{uuid:{3c621072-b317-4715-bb3e-c63ceb933735},repository:{dam},path:{/Portal/UK/Prescribing-links/Dupixent-AD-and-PN-GB-PI.pdf}}}">Prescribing Information GB</a></p>

<p><a href="${link:{uuid:{24d957f3-a739-4a69-83e2-5be7f4b65bff},repository:{dam},path:{/Portal/UK/Prescribing-links/Dupixent-AD-and-PN-PI-IE-XI.pdf}}}">Prescribing Information NI/ROI</a></p>

<h3>Immunosuppressant Cycling – Dr Richard Woolf&nbsp;&nbsp;</h3>
<p>Watch Dr Woolf discuss the impact of immunosuppressant cycling in people with moderate-to severe AD.&nbsp;</p>
<p>Video Playtime 3mins 01secs</p>
<p><b>&nbsp;</b>&nbsp;</p>

<h3><b>IL-4 in Type 2 Inflammation – Dr Alan Irvine&nbsp;&nbsp;</b></h3>
<p>Watch Dr Irvine discuss the role of IL-4 in AD.</p>
<p>Video Playtime 1min 46secs</p>

<h3><b>Immunological targets – Dr Richard Woolf&nbsp;&nbsp;</b></h3>
<p>Watch Dr Woolf discuss the immunological targets at play in AD.&nbsp;&nbsp;</p>
<p>Video Playtime 3mins 39secs</p>

<h3>Absence of monitoring requirement with DUPIXENT - Dr Thurein Ne Win</h3>
<p>Watch Dr Thurein Ne Win discuss the benefits of non monitoring with DUPIXENT.&nbsp;&nbsp;</p>
<p>Video Playtime 2mins 34secs</p>

<h3>RELIEVE-AD Results, long-term (3 years) treatment with DUPIXENT - Dr Stephan Weidinger</h3>
<p>Watch Dr Weidinger present 3-year results from RELIEVE-AD Data.</p>
<p>Video Playtime 1min 37secs</p>

<h3><b>Needle Phobia – Dr Tim Clayton&nbsp;</b>&nbsp;</h3>
<p>Watch Dr Clayton discuss needle phobia in adolescents and children with atopic dermatitis.</p>
<p>Video Playtime 4mins 14secs</p>

<h3>Dupixent in patients as young as 6&nbsp;months old with severe AD - expert panel discussion</h3>
<p>Watch a panel of experts&nbsp;discuss the practicalities of using DUPIXENT in children aged &lt;12 years through real-world case studies.&nbsp;</p>
<p>Video Playtime: 48mins 36secs<b><i>&nbsp;</i></b></p>

<h3>Patient Case Study IS Cycling - Dr Richard Woolf</h3>
<p>Watch Dr Woolf present a clinical case study of DUPIXENT use.&nbsp;</p>
<p>Video Playtime 3mins 12secs&nbsp;</p>

<h3>DUPIXENT use in a 3-year-old patient - Dr. Gabriela Petrof</h3>
<p>Watch Dr. Gabriela Petrof present a case study of the use of DUPIXENT in a 3-year-old patient with severe atopic dermatitis.</p>
<p>Video Playtime: 7mins 12secs&nbsp;</p>

<h3>DUPIXENT use in a child&nbsp;patient with severe AD - Dr. Inge Kreuser-Genis &amp; Emily King</h3>
<p>Watch Dr. Inge Kreuser-Genis and Emily King present a clinical case study of the use of DUPIXENT in an 8 year old patient with severe atopic dermatitis.</p>
<p>Video Playtime: 13mins 48secs</p>

<h3>Conjunctivitis Management - Mr Scott Robbie</h3>
<p>Watch Mr Scott Robbie discuss management of conjunctivitis in AD patients.</p>
<p>Video Playtime 1min 45secs</p>

<h3>Guy's and St Thomas' Conjunctivitis Patient Pathway - Mr Scott Robbie</h3>
<p>Watch Mr Scott Robbie present the&nbsp;Guy’s and St Thomas’ conjunctivitis patient pathway.</p>
<p>Video Playtime 4mins 24secs</p>

<h2>Patient Guides</h2>
<p>Please click below for available patient guides for patients prescribed with Dupixent:&nbsp;</p>

Atopic Dermatitis Control Tool (ADCT)

DUPIXENT (dupilumab) Prescribing Information GB

DUPIXENT (dupilumab) Prescribing Information NI/ROI

ATOPIC-DERMATITIS

DERMATOLOGY

Dupixent (dupilumab) Resources

<h2>Downloadable resources for patients who have been prescribed Cerdelga once or twice daily</h2>

<p>Support networks in Gaucher Disease</p>


Cerdelga®▼ (hard capsules eliglustat) prescribing information GB

Cerdelga®▼ (hard capsules eliglustat) prescribing information NI

GAUCHER

RARE-DISEASE

Cerdelga▼ eliglustat Patient Materials

<h2>Details</h2>
<p>Gauchers Association UK-based charity dedicated to raising awareness of Gaucher disease, and those affected and their families. They provide support and information for those affected by Gaucher disease.</p>

Patient Organisation Website

<p><strong>This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.</strong></p>
<p>Prescribing Information for SARCLISA<sup>®</sup>▼(isatuximab) can be found via the Product Card at the bottom of the page.</p>

<h2>Patient booklet</h2>
<p>This brochure is for you to provide to your patients once the decision has been made to prescribe SARCLISA<sup>®</sup>.</p>

<h2>Relapsed Refractory Multiple Myeloma Product</h2>

<p><a href="http://pro.campus.sanofi/uk/products/sarclisa">Learn more&nbsp; →</a></p>

<p><a href="https://pro.campus.sanofi/dam/jcr:6de3a21b-b60e-4a56-afea-e43468d285d6/Sarclisa%20PI%20GB%20May%202024_campus.pdf">Prescribing information GB</a></p>

<p data-font="small">MAT-XU-2202578 (v4.0)<br>
  Date of preparation: June 2024</p>
<p data-font="small">▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.</p>

SARCLISA®▼ (isatuximab) Prescribing Information GB

MULTIPLE-MYELOMA

ONCOLOGY

Helping your patients understand their treatment

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at <strong>{email}</strong> to confirm your account you can request a new one below. If you don't see it, you may need to <strong>check your spam</strong> folder.

title

In order to see <strong>relevant content</strong>, tell us what you are interested in

Title

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are now leaving the Sanofi campus UK website

You are about to leave Campus.sanofi/uk.

<strong>Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.</strong><br></br><br></br><br></br>

<strong>Please follow these steps to complete your registration:</strong><br></br><br></br>

<strong>Would you like to receive future text messages about Beyfortus updates?</strong>

<strong>Sanofi is here to help support your patients, their families, and caregivers.</strong><br></br><br></br>For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text.<br></br><br></br><strong>All fields are required.</strong>

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection?<br></br>Leave us your contact details, and a Sanofi representative will be in touch.

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Request a visit from your local ALTUVIIIO representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Request a visit from your local QFITLIA representative to learn more.<br></br><br></br>Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX.<br></br><br></br>Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

Sign up to schedule an office visit with your QFITLIA Representative or receive updates about QFITLIA.<br></br><br></br>Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>.<br></br><br></br><strong>All fields are required.</strong>

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v6.0) - Date of Preparation: April 2024

Welcome to Sanofi Campus UK

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. <br></br>Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Resources